Finance & Capital Markets

51. Anatomy Of A VC Deal With 4BIO's Dima Kuzmin & Ray Therapeutics' Paul Bresge 10/25/2022

    In a particularly candid conversation, 4BIO Managing Partner Dmitry ‘Dima’ Kuzmin and Ray Therapeutics Co-Founder & CEO Paul Bresge share the recipe for a successful relationship between biotech VC firm and startup. Bresge offers insight into VC engagement strategy and pitch, Kuzmin dishes on what investors look for in terms of "fundability" and what throws red flags, such as— perhaps ironically— a CEO like Bresge who has a deep and incredibly personal connection to the indication he's pursuing. The pair also discuss, in real and tangible terms, what constitutes a material, cultural match.

52. Picking Biotech Jockeys With SR One's Simeon George, M.D. 9/15/2024

    SR One Capital Management CEO Simeon George, M.D. has a seemingly innate ability to pick winning biotech builders. On the Business of Biotech, Dr. George shares insight into the decision-making processes that have contributed to his success at picking winners as an investment banker and biotech venture capitalist. Listen now!

53. Talking SPAC With Allan Shaw 7/27/2021

    Special-purpose acquisition companies, or SPACs, are all the rage as start-up financing vehicles go, and they're particularly well-suited for emerging biopharma companies. On this episode of the Business of Biotech, we dig deep into the advantages, limitations, and potential pitfalls of the SPAC with a man who was executing SPAC deals before SPAC deals were cool. Whether you're a biotech investor or a biopharma leader looking to acquire or be acquired, you'll want to tune in to this episode for insight into the special-purpose acquisition company strategy.

54. Pivoting To RNA With Circio's Dr. Erik Digman Wiklund 9/1/2024

    This week, it’s another “Business of Biotech-meets-Business-of-RNA” takeover with Circio CEO Erik Digman Wiklund, Ph.D. and guest co-host Anna Rose Welch of Advancing RNA. While Circio’s legacy is in cancer immunology (it still boasts a cancer vaccine candidate targeting KRAS driver mutations), the company made a bold pivot, of sorts, when it committed headlong to the circular RNA future. Now, it’s in the throes of fine-tuning a platform for the development of novel circRNA medicines for rare disease, vaccines, and cancer.

55. From Bayer To Startup Bio With AltruBio's Dr. Judy Chou 9/20/2021

    Judy Chou, Ph.D. was a big-pharma MVP. She earned her academic stripes in the hallowed halls of Yale, the Max Planck Institute, and Harvard Medical School before taking on principal scientist roles at AbbVie, Pfizer, and Genentech. That experience parlayed into SVP positions at Tanvex, Medvation, back to Pfizer, and on to Bayer, where she was most recently SVP and Global Head of Biotech before taking the leap into the startup scene as President & CEO at AltruBio in 2020. On today's episode of the Business of Biotech, Dr. Chou shares personal and professional insight into how she's applied what she learned in Big Bio to transform a clinical-stage developer of mAbs designed to treat a broad range of immunological diseases.

56. Biopharma Comebacks With Vincerx's Ahmed Hamdy, MD 6/28/2023

    Ahmed Hamdy, MD didn’t ask to be the subject of Nathan Vardi's new book​ For Blood and Money: Billionaires, Biotech, and the Quest for a Blockbuster Drug. In fact, he’d rather not relive that chapter.

57. Creating Competitive Differentiation With Allan Shaw 9/13/2021

    The biologic therapy market is crowded, and judging by the recent parade of IPOs, competition for investment, mindshare, talent, and ultimately share of market is only getting stiffer. On this week's episode of the Business of Biotech, our friend and biotech business guru Allan Shaw joins us for a foundational conversation on creating competitive differentiation at every stage of biopharma growth. We cover the connections between developmental strategy and the competitive commercial landscape, the moral obligation to differentiate between promise and plausibility, the commoditization of brilliant science, and the necessity to align balanced plans with wild dreams.

58. The Biotech Beatdown With Allan Shaw 6/6/2022

    On this, the 100th episode of the Business of Biotech podcast, our dear friend, frequent guest, and business of biotech brainiac Allan Shaw joins us to dissect the beleaguered biotech capital markets. We pick apart what's driving sentiment and how we got here, whether the industry is over-inventoried, what's getting funded , what's not, and why, and what biotech leaders should be doing in an investment landscape marked by hyper-discernment. We also reflect on the podcast journey and celebrate the 100-episode milestone!

59. Building Flagship Pioneering With Avak Kahvejian, Ph.D. 4/26/2023

    Flagship Pioneering is fertile ground for a bevy of blossoming biotechs, and one of its most prolific sowers is General Partner Avak Kahvejian, Ph.D. Dr. Kahvejian counts Seres Therapeutics, Rubius Therapeutics, Codiak BioSciences, Cygnal Therapeutics, Ring Therapeutics, Cellarity, Laronde, and Generate Biomedicines among the companies he's played a leading hand in launching. On this episode of the Business of Biotech, Kahvejian takes us under the hood of one of the most burgeoning businesses in biotech, sharing details on the people, processes, and technologies fueling its rapid growth.

60. Biopharma PR 101 With Matt Middleman, M.D. 7/6/2021

    When is the appropriate time for a new life sciences company to wind up the PR machine? What's the difference between public and investor relations, and how do they complement each other? What's newsworthy? What's not? What are the latest tools of the trade in an increasingly social-driven PR practice? What results should you expect, and how are those results measured? On this episode of the Business of Biotech, we address these questions with physician and professor-turned public relations practitioner extraordinaire Matt Middleman, M.D. , founding partner and CEO at LifeSci Communications, LLC.